Compare Recursion Pharmaceuticals Inc (RXRX) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs BlackRock TCP Capital Corp — how do they compare? Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.81B), while BlackRock TCP Capital Corp trades at $3.93 (market cap $327.64M). The key difference: Recursion Pharmaceuticals Inc is far larger — about 5.5× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 19.46% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | TCPC | |
|---|---|---|
Market Cap | $1.81B | $327.64M |
Sector | Health | Financials |
52-Week High | $6.79 | $7.26 |
52-Week Low | $2.84 | $3.13 |
Enterprise Value | $1.33B | — |
Dividend Yield | — | 19.46% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
